454 results about "Neurophysins" patented technology

The invention discloses novel application of notoginsenoside Rg1, namely application of the notoginsenoside Rg1 in preparation of a cathepsin D (CTSD) inhibitor, the notoginsenoside Rg1 can inhibit CTSD enzyme activity so as to recover lysosome structure and function, relieve endoplasmic reticulum stress reaction and relieve alpha-syn aggregation and dopaminergic neuron apoptosis, has a remarkable protection effect on a Parkinson's disease model, and can be used for preparing a novel anti-inflammatory drug. The invention provides a new thought and a potential drug basis for targeted intervention of Parkinson's disease. The invention discloses a new mechanism that Rg1 plays a role in neuroprotection through a CTSD-lysosome-endoplasmic reticulum stress pathway.

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg / day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition with an anti-depression effect, which is prepared from the following medicinal materials by weight: 6g of pericarpium citri reticulatae viride, 6g of pericarpium citri reticulatae, 6g of radix paeoniae alba, 6g of thunberg fritillary bulb, 4.5 g of rhizoma alismatis, 4.5 g of fried gardenia and 4.5 g of moutan bark. The composition regulates functions of hypothalamus-pituitary-adrenal axis (HPA axis) and repairs hippocampal neurons and relieves symptoms such as pleasant sensation loss and behavioral despair of depression patients by relieving qi stagnation, clearing heat, cooling blood, promoting diuresis and reducing phlegm. Experiments prove that the traditional Chinese medicine composition can remarkably improve the sweet water preference rate of depression rats, shorten the forced swimming immobility time, reduce the levels of CRH, ACTH and CORT of plasma and improve pathological injuries of hippocampus tissues. The composition adopts medicinal and edible medicinal materials, is small in side effect and high in safety, and can be prepared into an oral preparation for treating depression.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The invention discloses application of PGRN in preparation of products for preventing and treating neuropsychiatric disorder related diseases caused by estrogen deficiency. The invention provides an application of a PGRN protein or a coding gene thereof or a virus expressing the coding gene thereof in preparation of a product with any one of the following functions: 1) preventing or treating or saving neuropsychiatric disorder related diseases caused by estrogen deficiency; 2) preventing or treating perimenopausal anxiety and / or depression symptoms; and 3) relieving anxiety-like behaviors and / or depression-like behaviors caused by estrogen deficiency. The application proves that the PGRN can play a role in protecting neuron damage caused by estrogen deficiency by rescuing CTSD enzyme activity and an autophagy pathway, and prompts that related medicines and measures influencing secretion and content of the PGRN can treat perimenopausal anxiety and depressive symptoms; and a new target and a new idea are provided for clinical treatment and drug development of anxiety and depression symptoms of climacteric women.

The invention relates to the technical field of environmental health risk evaluation, in particular to a method for evaluating the risk of Parkinson's disease induced by environmental pollutants. The method for evaluating the risk of inducing the Parkinson's disease by the environmental pollutants comprises the following steps: carrying out a subacute exposure experiment by taking caenorhabditis elegans as a model organism; observing the transport capacity of the caenorhabditis elegans, observing and counting the abnormal movement ability of the caenorhabditis elegans, and determining the lipofuscin level of the caenorhabditis elegans, the damage degree of dopaminergic neurons, the dopamine level and the expression and aggregation conditions of alpha-synuclein protein, so as to evaluate the risk of the Parkinson's disease induced by environmental pollutants; the environmental pollutant is 6: 2 chlorinated polyfluoroalkyl ether sulfonate. According to the method, the PD toxicity evaluation model is generated by constructing a behavior characteristic and molecular characteristic scheme and combining multi-strain nematode data, and the problem that in the prior art, the risk of inducing PD by environmental pollutants is difficult to comprehensively reveal due to the fact that a single dimension is concerned is solved.

The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

The invention provides application of ACT001 in preparation of a medicine for treating spinal cord injury, and relates to the technical field of biomedicine. The parthenolide structure-improved compound ACT001 disclosed by the invention, as a novel neuroprotective drug, has a remarkable effect, and can be used for practically relieving inflammatory response after spinal cord injury, inhibiting formation of glial scars after injury and protecting neurons so as to promote functional recovery. The medicine can improve the lower limb function recovery of the SCI patient, improve the life quality of the patient, and bring a brand new treatment choice for acute and chronic spinal cord injury patients.

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention provides application of adiponectin and an adiponectin receptor agonist in treatment of amyotrophic lateral sclerosis. The invention finds that the plasma adiponectin level of an ALS patient is related to the inflammatory factor level, and finds that AdipoR1 and AdipoR2 in the ALS patient are remarkably up-regulated and are related to M1 type macrophage activation. Experiments prove that the adiponectin receptor stimulant can relieve the proinflammatory response of macrophages, regulate the polarization of the macrophages and protect neurons, and the adiponectin receptor stimulant can postpone the occurrence of dyskinesia of ALS patients and prolong the lifetime of the ALS patients. The invention provides a new strategy for diagnosis and treatment of ALS, and has a good clinical application prospect.

The invention relates to the technical field of biological medicine, in particular to application of halofuginone in medicine for treating spinal cord injury. The invention provides application of halofuginone in preparation of a medicine for treating spinal cord injury, application of halofuginone in preparation of a medicine for promoting spinal cord injury repair and application of halofuginone in preparation of a medicine for promoting exercise ability recovery after spinal cord injury. The therapeutic drug can promote functional recovery after spinal cord injury, inhibit activation of microglial cells after spinal cord injury and reduce inflammatory response. In addition, the treatment medicine can prevent neuronal reduction after spinal cord injury.

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The invention discloses application of ginsenoside Rg5 in preparation of a medicine for treating Alzheimer's disease and an evaluation method, and relates to application of ginsenoside Rg5 in preparation of a medicine for treating Alzheimer's disease. The medicine improves A beta deposition, tau protein phosphorylation and neuron damage by adjusting the intestinal flora structure and metabolite level, and is used for relieving the pathological process of the Alzheimer's disease. The invention has the characteristics of multi-target effect, nerve protection, inflammation resistance and oxidation resistance.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention discloses a preparation method and application of a sepsis-related encephalopathy model based on HLA II type gene humanized mice. According to the invention, HLA DP401 / DRA-IA beta- / -transgenic humanized mice are utilized, and the HLAII type gene humanized mouse sepsis model is prepared through mouse cecum seroperitoneal infection (CS) and meropenem intervention. The sepsis encephalopathy model can be comprehensively evaluated through indexes such as clinical score MSS, serum and hippocampal tissue inflammatory cytokine detection, hippocampal tissue microglial cell activation, hippocampal neuron spinous process change, transcriptomics, behavioral change and the like, and the sepsis encephalopathy model can be used for screening therapeutic drugs and therapeutic schedules; the HLA II type gene humanized mouse sepsis-related encephalopathy model provided by the invention can be used for infectious encephalopathy pathogenesis research, new drug research and development and safety evaluation.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

The invention discloses a traditional Chinese medicine composition for improving cerebral ischemia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparation. The preparation method comprises the following steps: mixing, stirring and dispersing a polyurethane pressure-sensitive adhesive, a copper sulfide-polyacrylate glue solution, mixed traditional Chinese medicine powder, ethyl acetate and a penetration enhancer, and standing to obtain a drug-loaded composite pressure-sensitive adhesive; and coating a polyethylene backing layer with the drug-loaded composite pressure-sensitive adhesive, and then drying, evaporating and curing to obtain the traditional Chinese medicine composition. Ginseng is used as a monarch drug, astragalus membranaceus is used as a ministerial drug, fructus aurantii, caulis spatholobi, poria cocos, gastrodia elata and coptis chinensis are used as adjuvant drugs, and liquorice is used as a conductant drug, so that the whole traditional Chinese medicine composition can enhance qi and blood, improve microcirculation, protect neurons and reduce ischemia consequences, and can regulate the drug properties of all the drugs to play a synergistic effect. And then preparing the traditional Chinese medicine composition patch with photo-thermal penetration promotion to realize the treatment of cerebral ischemia.

The invention discloses a strain for preventing and treating Parkinson's disease as well as a composition, application and a product thereof, and relates to the technical field of microorganisms. The invention provides three strains from human milk, namely lactobacillus helveticus LV-20, plant lactobacillus LPP8 and lactobacillus fermentum PL-15, the invention further provides a composition capable of preventing and treating the Parkinson's disease, and the three strains can well prevent and treat the Parkinson's disease and can be used for preventing and treating the Parkinson's disease. The composition can significantly improve dyskinesia (such as static tremor, muscle stiffness, movement retardation, posture balance and the like), reduce neuron damage, significantly reduce alpha-syn deposition, reverse sensory function degradation and cognitive disorder, relieve sleep disorder, inhibit neuroinflammation and oxidative stress, reduce and repair intestinal barrier damage, relieve gastrointestinal dysfunction, and improve the curative effect. As probiotics or synbiotics, products for treating and preventing Parkinson's disease have a wide application prospect.

The invention discloses application of a mitochondrial differentiation expression gene in preparation of a depression diagnostic agent and a depression treatment drug, and relates to the technical field of depression diagnosis and treatment. And the mitochondrial differentiation expression gene comprises one or more of TFAM (Transforming Factor Amplification Molecular), SURF1 and NDUFB9. According to the present invention, the SURF1 gene simultaneously expressed in inhibitory neurons and excitatory neurons is focused on, the key effect of the SURF1 in CUMS-induced depression-like behaviors is found, the CUMS-induced molecular and behavior changes are effectively reversed by the overexpression of the SURF1, and the potential anti-depression effect is displayed; besides, animal experiments find that overexpression of the SURF1 can effectively recover the function of an electron transport chain, ATP generation is enhanced, mitochondrial membrane potential is maintained, and oxidative stress is reduced. The effects jointly relieve depression-like behaviors induced by CUMS, and further support the protection effect of the SURF1 in a depression model, which provides evidence for the new effect of the SURF1 in the pathophysiology of depression.

A topical neurocosmetic composition comprising a first component including one or more of bakuchiol, allantoin, squalane, or Morinda citrifolia extract; a second component including one or more of hyaluronic acid, vitamin E, Zanthoxylum alatum fruit extract, Coriandrum sativum seed oil, Vitex agnus-castus extract, Helianthus annuus sprout extract, niacinamide, resveratrol, or an ascorbyl ester; and a cosmetically acceptable oil-in-water vehicle configured to deliver both lipophilic and hydrophilic actives through the skin to dermal neurons. The composition improves measurable skin parameters such as hydration and elasticity and supports psychophysiological comfort. Methods of manufacture and use are also described

The invention relates to a dietary therapy formula for improving microcirculation of inner ears and a preparation method. Components with homology of medicine and food are selected, the black rice, the blueberries and the purple cabbages are rich in anthocyanin and beneficial to removing free radicals in cochlea and inhibiting hair cell apoptosis, the walnut kernels and the Chinese wolfberry fruits can improve blood vessel elasticity and protect auditory neurons, and the radix salviae miltiorrhizae, the hawthorn fruits and the radix puerariae can increase blood flow of inner ears, promote nutrition delivery, reduce blood viscosity and reduce vasospasm, so that the health-care food is suitable for being eaten by people. The whole component is low in sugar content, suitable for diabetics and capable of expanding the crowd. Effective components are processed into non-medicinal products, food therapy is beneficial to improving microcirculation of inner ears, relieving ear symptoms such as tinnitus and the like and delaying hearing loss, and a user can eat the food for a long time without psychological burden of medication.

The invention relates to the field of natural medicinal chemistry, and discloses an efficient separation and preparation method of a compound theanine diglucoside TFG. Although TFG structures are reported, separation from tea leaves is not disclosed. According to the invention, an efficient separation and purification method is established for the first time, and TFG is accurately extracted and identified from tea leaves by combining an HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector) guided multi-stage column chromatography technology with nuclear magnetic resonance and mass spectrometry. Experiments prove that the TFG activates an antioxidant pathway, improves H2O2-induced HUVEC cell and HT22 cell damage, protects the vascular endothelial barrier function and neuronal activity, and is suitable for developing antioxidant drugs for treating Alzheimer's disease. Compared with the prior art, the invention fills the blank of separation of the tea-derived TFG, explores the new application of the tea-derived TFG in the field of cell protection, and provides a new thought for natural product development and functional food research.

The invention discloses a perillaldehyde benzyl derivative, a synthesis method thereof and application of the perillaldehyde benzyl derivative in preparation of a drug for resisting brain neuron dysfunction. According to the technical scheme, the perillaldehyde benzyl derivative is characterized in that the perillaldehyde benzyl derivative is 2-phenyl-1-(4-isopropenylcyclohex-1-ene) ethanone, the structural formula of the perillaldehyde benzyl derivative is shown in the specification, and the invention further specifically discloses a synthesis method of the perillaldehyde benzyl derivative and application of the perillaldehyde benzyl derivative to preparation of drugs for resisting brain neuron dysfunction. The perillaldehyde benzyl derivative synthesized by the invention can be used as an NMDAR2B agonist to act on NMDAR2B in a targeting manner, meanwhile, a p-PI3K / p-AKT signal channel is activated, the expression levels of NOX2 and NOX4 are inhibited, and the effect of resisting neuronal dysfunction is achieved.

The invention relates to application of 1-allyl piperazine or pharmaceutically acceptable salt thereof in preparation of a medicine for treating Parkinson's disease. A caenorhabditis elegans PD model is adopted to prove for the first time that on one hand, 1-allyl piperazine can obviously enhance autophagy activity in a model animal body, efficiently promote removal of aggregation alpha-synuclein and radically relieve damage of Parkinson's disease characteristic pathological protein deposition to neurons, and on the other hand, 1-allyl piperazine can effectively promote removal of aggregation alpha-synuclein and radically relieve damage of Parkinson's disease characteristic pathological protein deposition to neurons. The compound can effectively activate mitochondrial unfolded protein reaction. The autophagy activation pathway and the mitochondrial function regulation pathway can generate a synergistic effect to jointly relieve the neurodegeneration process related to the Parkinson's disease, so that dopaminergic neurons are protected, and the pathological progress of the disease is delayed.

The invention discloses a pharmaceutical composition for treating KCNQ2 developmental epileptic encephalopathy, a nucleic acid construct and application of the pharmaceutical composition and the nucleic acid construct. According to the invention, by introducing a nucleic acid construct carrying the hKCNQ2 gene into a KCNQ2A294V / + developmental epileptic encephalopathy animal model and a human forebrain neuron model, the effectiveness of the nucleic acid construct in improving the expression level of the KCNQ2 and improving related neuropathological mechanisms is verified. Not only is a new hope provided for treatment of KCNQ2-related developmental epileptic encephalopathy provided, but also a new direction is opened up for application of gene therapy in neurodevelopmental diseases.

The application discloses a preparation method and application of a conjugate targeting pelvic autonomic nerves, wherein the conjugate is NE-RH formed by coupling of rhein and norepinephrine, the conjugate can realize precise targeting of norepinephrine neurons, improve the accumulation effect of RH in the norepinephrine neurons, and further enhance the nerve protection effect of RH. The conjugate has a molecular weight of less than 1000 Da, can help to penetrate the blood-brain barrier, and can avoid the defects of being easily removed by a mononuclear phagocyte system and having a short half-life. The production process of the conjugate is simple, the chemical coupling reaction is clear, the yield can reach 38%, and the purity of the product is greater than 99%, so that the conjugate is convenient to popularize and use. The conjugate and the preparation method have important significance for the damage repair of pelvic autonomic nerves.